The Pan Probe Biotech, Inc., LiveSure^TM Benzodiazepines Screen Test is an in vitro diagnostic (IVD), qualitative, lateral flow, immunochromatographic urinary assay for the rapid detection of benzodiazepine and its metabolites in human urine at the Substance Abuse Mental Health Services Administration (SAMHSA) cut-off level of 300 ng/ml.  Benzodiazepine is the most widely prescribed anxiolytic drug and is used extensively as an anti-anxiety agent, a hypnotic, a muscle relaxant and an anti-convulsant.  Benzodiazepine is usually taken orally, or by intravenous or intramuscular injection.  High dose abuse of benzodiazepine can result in drowsiness and confusion, and potentiates alcohol and other CNS depressant drugs.  The LiveSure^TM Benzodiazepines Screen Test is a competitive immunoassay in which chemically modified and bound benzodiazepine conjugate competes with urinary benzodiazepine and its metabolites for limited, specific benzodiazepine antibody binding sites.  Each test device contains a sample reaction unit, a pink-colored, antibody-colloidal gold conjugate unit pre-labeled with specific antibody, and a chromatographic membrane pre-coated with drug conjugate in the device test region.